Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,280 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Disease Transmission, Vertical, Vertical Human Immunodeficiency Virus Transmission, HIV Infections
Interventions: Zidovudine, Nevirapine (NVP), Epivir (3TC), Nelfinavir (NFV); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Up to 2 Days
Enrollment: 1,735 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 5
States / cities: Long Beach, California • Gainesville, Florida • Jacksonville, Florida + 2 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: Lisa A. Marsch; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Coronavirus Infection
Interventions: NasoVAX, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Miami, Florida • Morrow, Georgia • Chicago, Illinois + 3 more

Conditions: Cardiopulmonary Arrest, Fungal Infection
Interventions: Fluconazole; Drug
Lead sponsor: Michael Cohen-Wolkowiez; Other
Eligibility: Up to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Covid19
Interventions: Hydroxychloroquine Sulfate (HCQ); Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Edison, New Jersey

Conditions: Hepatitis B
Interventions: Vaccination to prevent hepatitis B virus infection; Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 595 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 3
States / cities: Hartford, Connecticut • Chicago, Illinois • Cleveland, Ohio

Conditions: Sexual Risk Behavior, Drug Use, Family Functioning
Interventions: eHealth Familias Unidas Primary Care; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 12 Years to 17 Years
Enrollment: 921 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Hialeah, Florida • Miami, Florida

Conditions: Fractures, Open, Infections
Interventions: Cefazolin, Cephalexin; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 0 Years to 17 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Allergy, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Interventions: Not listed
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: 6 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COVID 19
Interventions: MR or M-M-R II ® vaccine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 3,411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Infections
Interventions: Infeccion de Amor (Love Infection); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Staphylococcal Infections, Surgical Site Infection
Interventions: XF-73, Placebo; Drug
Lead sponsor: Destiny Pharma Plc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Gainesville, Florida • Pocatello, Idaho • Des Moines, Iowa + 4 more

Conditions: Surgical Site Infections, Post Operative Complication
Interventions: 2% chlorhexidine gluconate cloths; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 19 Years to 90 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Malaria
Interventions: VRC-MALMAB0114-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
Interventions: Islatravir, Placebo to FTC/TDF, FTC/TDF, Placebo to ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 730 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more

Conditions: Pars Plana Vitrectomy, Scleral Buckling, Surgical Outcomes, Infection Prophylaxis
Interventions: Not listed
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Kidney Transplant, Liver Transplant
Interventions: Letermovir; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections
Interventions: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 39 Years
Enrollment: 1,219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: Oseltamivir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Los Angeles, California • Palo Alto, California • Bethesda, Maryland + 1 more

Conditions: Dengue Fever
Interventions: rDEN3delta30/31-7164; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Clostridium Difficile Diarrhea
Interventions: Metronidazole, Placebo; Drug
Lead sponsor: Alison Schneider; Other
Eligibility: 55 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions: VE303, Placebo; Drug
Lead sponsor: Vedanta Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 29
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more

Conditions: Sexually Transmitted Diseases, Safe Sex, Adherence, Medication
Interventions: P3+, Control; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years · Male only
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Urinary Tract Infections
Interventions: Nitrofurantoin, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

Using Social Media to Deliver HIV Self-Testing Kits and Link to Online PrEP Services

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Pharmacokinetics/Pharmacodynamics (PK/PD) of Fluconazole in Children on Extracorporeal Membrane Oxygenation (ECMO)

Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers

Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules

eHealth Evidence-based Intervention (EBI) for Latino Youth in Primary Care

Antibiotic Prophylaxis in Pediatric Open Fractures

Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION

Love Infection: A Dramatized Story Intervention (Telenovela/Soap Opera) for HIV Prevention

Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection

2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients

Trial to Evaluate L9LS in Healthy Adults

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Necessity of Post-operative Eye Drops

Letermovir for R+ Study

Botswana TDF/FTC Oral HIV Prophylaxis Trial

Alternative Oseltamivir Dosing Strategies

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults

Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

P3 (Prepared, Protected, emPowered)

Nitrofurantoin and Urinary Tract Infections (UTIs)